TouchDown Therapeutics Revenue and Competitors

AAV-based products are already transforming some diseases. However, the current toolkit is limited by selectivity, potency, pre-existing immunity and costs of production. There is a significant need for new technologies that enable better therapeutics to benefit more patients. We are leveraging a unique collection of assets to invent novel, superior vectors that are better suited for specific disease strategies. Our scientific assets comprise an unprecedented library of functional viruses, unique high-throughput screening methods and vast datasets that are being mined by modern computing power. Each experiment delivers new insights into capsid biology, often with clear therapeutic applications. Our unique scientific positioning is underpinned by leading scientific talent and a track record of success. We believe that sustained, patient investment in innovative science will deliver substantial long-term value to our stakeholders. We are committed to translating our proprietary science and capabilities into high impact, differentiated therapeutics to transform human healthcare. We are TouchDown Therapeutics.